As we drive toward curing type 1 diabetes, we help make everyday life better for the people who face it. We are Breakthrough T1D.
Headquarters in New York, NY
Joined February 2009
- Tweets13.8K
- Following1.5K
- Followers62.7K
- Likes5.5K
Diabetes Tipo 1 y Comunidad: Experiencias que Inspiran, Educan y Generan Impacto xitter.twitterapi.xyz/i/broadcasts/2qVXpyNXp…
"The thing that changed my life the most was never going low."
Katie Beth Hand was diagnosed with T1D at age 26 and spent years struggling with severe hypoglycemia. In January 2026, she enrolled in a Breakthrough T1D-funded clinical trial studying Eledon’s tegoprubart at the University of Chicago.
Today, she is insulin-free.
Watch Katie Beth's full conversation with our CEO to hear her story and learn more about the research that is helping advance the future of T1D treatment. youtube.com/watch?v=SLCLTYjs…
Breakthrough T1D retweeted
"Our central recommendation, which we first presented to Secretary Kennedy on March 6, 2026, is that HHS define unmodified DDI as organs under the National Organ Transplant Act (NOTA), so that this therapy is overseen through HRSA and the Organ Procurement and Transplantation Network (OPTN), while FDA retains jurisdiction over manufactured cell therapies and modified DDI."
Read the full submission here: breakthrought1d.org/news-and…
#Nationaldiabetesawarenessmonth #T1D
Breakthrough T1D retweeted
Today @BreakthroughT1D submitted our response to the Department of Health and Human Services' Request for Information on Deceased Donor Islet Classifications. SVP of Global Advocacy Campbell Hutton explains our approach, where we are in the process, and what we'll do to keep progress moving.
November is National Diabetes Awareness Month (NDAM), and it’s a great time to share your story, spread awareness about type 1 diabetes (T1D), and help people around the world #SeeT1D.
T1D impacts over 9.5 million people around the world across every age, background, and community. Behind every statistic is a real person, a family, and a story that deserves to be seen and understood.
Learn more at SeeT1D.org
Breakthrough T1D’s first-ever Clinical & Research Congress (CRC 2026), focused entirely on type 1 diabetes (T1D), wrapped up just over two weeks ago! To check out all our coverage from the exciting weekend in Philadelphia, PA, where researchers, clinicians, industry leaders, healthcare professionals (HCPs), and the T1D community united to share updates across our entire mission, click here: bit.ly/4irsdNE
Thanks for joining us throughout our coverage of our Clinical & Research Congress! And thank you to everyone who helped make this conference possible, including our sponsors, donors, supporters, and staff. We couldn’t do this without you.
We couldn’t be more proud of how our inaugural conference turned out, and we’re already looking forward to next year. Mark your calendars: CRC 2027 will take place in Washington, D.C., from October 15-17, 2027!
Anyone who runs a marathon has something driving them for all 26.2 miles of their race. For Emily, that’s her daughter, Kendall, who lives with type 1 diabetes (T1D). Emily is running the New York City Marathon next Sunday with Breakthrough T1D to help us continue to power breakthroughs in T1D research!
Want to learn more about running with Breakthrough T1D? Visit the link below!
bit.ly/4iy7LM5
There is something special about a Breakthrough T1D Walk! Walk day unites our community to accelerate life-changing type 1 diabetes (T1D) research, and provides an opportunity to connect with other people living with and impacted by T1D, and so much more!
To find a walk near you, visit walk.breakthrought1d.org!
1
5
930
Katie Beth Hand took part in a Breakthrough T1D-funded clinical trial of an investigational immune therapy for type 1 diabetes tested with an islet transplant, and she’s been off insulin for over 200 days.
DA Gros, M.D., is the CEO of Eledon, the company that developed that investigational therapy, called tegoprubart.
Here, with Lynn Starr, Breakthrough T1D Chief Global Advocacy Officer, they meet face to face for the first time.
See an excerpt for their conversation about life post-islet transplant, the work behind the breakthroughs, and the pathway to therapies that will one day allow everyone to take off their pumps and CGMs for good and watch the full conversation here: bit.ly/3VPUqWK
A new clinical trial for Eledon Pharmaceutical's tegoprubart is underway — and the first participant with type 1 diabetes (T1D) and reduced kidney function has received their islet transplant!
Breakthrough T1D is funding a clinical trial at the University of Chicago and the University of Miami that replaces tacrolimus, a traditional immunosuppressant, with tegoprubart, a milder and more targeted alternative, in islet transplants for people with T1D and reduced kidney function. Tacrolimus can damage the kidneys and the transplanted islet cells, so people with reduced kidney function have previously been excluded from these transplants.
Nearly a third of people with T1D will develop kidney disease. This study could open islet transplants to a larger population of people with T1D.
Learn more here: breakthrought1d.org/news-and…
Breakthrough T1D retweeted
🎥 In this #HealioExclusive video from the @BreakthroughT1D Clinical and Research Congress, Dr. Chantal Mathieu of @KU_Leuven highlights how type 1 #diabetes care could undergo a huge transformation in the near future.
@GoHealio
vist.ly/5nhfe
Day 2 of our Clinical Research Congress brought incredible conversations surrounding global collaboration, unmet needs for those in the type 1 diabetes (T1D) community, disease modifying therapies, and more. We are extremely thankful to have so many brilliant minds together in one place helping move us toward cures and improving lives for everyone living with T1D. Click here for the full recap: breakthrought1d.org/news-and…
Jim Lurie, whose parents, Carol and Erwin, were two founders of our organization over 50 years ago, kicks off the third and final day of the inaugural Breakthrough T1D Clinical and Research Congress.
Stay tuned for more news and updates as we wrap up an incredible weekend, back where it all began here in Philadelphia.
Breakthrough T1D retweeted
Everyone can be an advocate for T1D, especially when the question is whether or not to federally fund cure research. CEO @aaronjkowalski breaks down what's at stake with the Special Diabetes Program at @BreakthroughT1D's inaugural Clinical and Research Congress. Go to breakthrought1d.org/advocacy to join the effort.
Hearing the lived experiences of patients with type 1 diabetes (T1D) like Ramya and Ben gives Breakthrough T1D funded researchers a unique perspective on the real-world impact of their work.
Be sure to stay tuned this weekend across our social channels as we bring you the latest and greatest T1D research news coming out of the inaugural Breakthrough T1D Clinical and Research Congress!
Breakthrough T1D retweeted
No one understands type 1 diabetes better than the people who live with the realities of it every day. Empowering the community has had incredible results, from improving devices and expanding coverage to securing federal research funding and accelerating new therapy approvals. @BreakthroughT1D Chief Executive Officer @aaronjkowalski joined the @MilkenInstitute to talk about the power of Breakthrough T1D's advocates and the need for the community to continue to lead the conversation on treating, covering, and curing T1D.
There's more work to do, go to breakthroughT1D.org/advocacy to become an advocate today. #T1D #SeeT1D #T1DLooksLikeMe
Breakthrough T1D retweeted
Cell therapy research is a critical component in the mission to cure type 1 diabetes. Today, @BreakthroughT1D Chief Executive Officer @aaronjkowalski, Chief Scientific Officer Sanjoy Dutta, and Chief Global Advocacy Officer @LynnStarrDC met with @NIHDirector_Jay Bhattacharya to discuss how we can keep these groundbreaking therapies and others moving forward. We're grateful for Dr. Bhattacharya's support and leadership. #t1d
ICYMI: Katie Beth Hand was featured on NBC Nightly News!
Katie Beth is a participant in a Breakthrough T1D-funded clinical trial at the University of Chicago that is pairing deceased donor islet transplants with tegoprubart, an investigational therapy by @Eledon_Pharma to protect transplanted cells without the harsh side effects of traditional immunosuppressants.
13 years after her diagnosis, Katie Beth is off external insulin.
We're proud to support this research and grateful to Katie Beth for sharing her story and participating in this study.
Watch the feature here: youtube.com/watch?v=Tx1GXI62…
If you or someone you know lives with type 1 diabetes (T1D) and is in the path of #HurricaneNolo make sure you're prepared! Visit the link below for helpful resources and stay safe!
bit.ly/3BeTUaf
